Drug Search Results
More Filters [+]

Danoprevir

Alternative Names: danoprevir
Latest Update: 2024-02-14
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: HCV-NS3/4A Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Hoffmann-La Roche
Company Location: BASEL SWITZERLAND V8
Company CEO: Severin Schwan
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Danoprevir

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 4: COVID-19

Phase 3: Hepatitis C, Chronic

Phase 2: Hepatitis C, Chronic|Hepatitis A|Hepatitis C

Phase 1: Healthy Volunteers

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

C-DIAMOND

N/A

Unknown status

Hepatitis C, Chronic|Hepatitis A

2021-07-31

ChiCTR2000031734

N/A

Recruiting

Pneumonia|COVID-19

2020-05-29

ChiCTR2000030259

N/A

Recruiting

Pneumonia|COVID-19

2020-04-30

ASC-CTP-HS-01

P4

Completed

COVID-19

2020-04-15

Recent News Events